Hugh Martin

Hugh Martin is Chairman and Interim Chief Business Officer of Pendulum Therapeutics, a biotechnology company pioneering microbiome science to transform human health. He earned a BS in electrical engineering from Rutgers, the State University of New Jersey-New Brunswick.

Martin brings a distinguished career spanning over three decades as an entrepreneurial leader of technology ventures. In 2011, he was named CEO for Fortune magazine's "Executive Dream Team: The startup edition," acknowledged for his "management chops" and for successfully taking public two companies, in two different industries. The World Economic Forum recognized Hugh and Sensity as a Technology Pioneer, and he created the vision for Sensity Systems and the Light Sensory Network.

Career History

• Chairman & Interim Chief Business Officer, Pendulum Therapeutics (July 2023–present)
• Chairman & CEO, Lacuna Technologies (November 2019–August 2023)
• VP IoT Platforms & SCV Strategy, Verizon (October 2016–October 2018)
• Chairman & CEO, Sensity Systems, which created the Light Sensory Network (2012–2016)
• Founder and Chairman & CEO, Pacific Biosciences, which he piloted through its IPO in 2010 and commercialization in 2011
• Founder, Chairman, President & CEO, ONI Systems (1998–2002), a high-speed optical telecommunications company taken public in 2000 and sold to Ciena in 2002
• President and Director, 3DO, an interactive gaming company
• CEO-in-residence, Kleiner Perkins Caufield & Byers
• Desktop engineering, Apple Computer
• Founder, Ridge Computers, designer of the world's first commercial RISC minicomputer

What Hugh Martin could bring to his role at Pendulum Therapeutics: Martin's extensive track record building and scaling high-growth technology companies, combined with his success taking multiple companies public across different industries (telecommunications and sequencing), positions him to drive Pendulum's commercial expansion in the rapidly scaling microbiome therapeutics market. His experience navigating complex science-based ventures and his recognized expertise in emerging technology platforms suggest he could help accelerate Pendulum's clinical validation and market penetration as a biotech pioneer.

This is an automatically generated Light profile created by Executive Moves editorial systems from verified public announcements. Information is kept deliberately concise until the page is claimed and enriched.